Aim Immunotech Inc. · AMEX:AIM
Aim Immunotech — Investor Presentation (January 2022)
27 slides from Aim Immunotech's investor presentation, Jan 26, 2022
Slide 1: AIM ImmunoTech
AIMIMMUNO.COM NYSE AMERICAN:AIM AIM ImmunoTech
Slide 2: Forward-Looking Statements
Forward-Looking Statements Some of the statements included in this presentation may be forward-looking statements that involve a number of risks and uncertainties. Among other eH, for those statements, we claim the protection of safe harbor for forward-looking statements contained in the Private Sec
Slide 3: Investor Highlights
Investor Highlights We are an immuno-pharma company focused on the development of therapeutics to treat multiple types of cancers, viral diseases and immune-deficiency disorders i potentially applicable in multiple high-value indications Approved in Argentina as Six (6) ongoing oncology Antiviral st
Slide 4: Broad Oncology Pipeline Across High-Value Indications
Broad Oncology Pipeline Across High-Value Indications |ImmunoTech Indications Ovarian Cancer (Advanced, Recurrent) Colorectal Cancer (Metastatic) Breast Cancer (Metastatic Triple-Negative) Ovarian Cancer (Advanced, Recurrent) Prostate Cancer (Early-Stage) Pancreatic Cancer Breast Cancer (Early-Stage
Slide 5: Extensive Viral and Immune System Disorder Pipeline
Extensive Viral and Immune System Disorder Pipeline lida me Viral Infections Combination: Interferon \. " Immune System Disorder Severe CFS Single Agent | Approved in evere ingle Agent | Argentina iF nd ME/CFS Single Agent Planning 27 phase ‘ | 3 Confirmatory Trial Post-COVID-19 singleiagent Under i
Slide 6: Proven Management Team
Proven Management Team Thomas K. Equels, M.S., J.D. © — nN Chief Executive Officer BIOFLORIDA Maz aw Fre (il Greenbergtraurig David R. Strayer, M.D. Chief Scientific & Medical Officer se. Peter W. Rodino III, J.D. Chief Operating Officer, Executive Director for Governmental Relations, General Counse
Slide 7: Lead Program Ampligen (rintatolimod)
immunoTech Lead Program Ampligen (rintatolimod) Significant Opportunity Across Multiple Disease Areas Approved for the treatment of severe Immu no-Oncology CFS in Argentina Generally well-tolerated with over 100,000 IV doses in humans Virology Clinically tested as a single-agent therapeutic and in c
Slide 8: Ampligen: Immuno-Therapy Targeting Multiple Cancers with High-Unmet Need
Ampligen Immuno-Therapy Targeting Multiple Me Cancers with High-Unmet Need
Slide 9: Mechanism of Ampligen Induces Wide Range of Immunologic and Antitumor Activities
Mechanism of Ampligen Induces Wide Range of Immunologic and Antitumor Activities Immuno-modulator that selectively activates TLR3 pathway Exclusively activates TRIF adaptor and avoids MyD88 inflammatory pathway used by all other TLRs! Promotes selective attraction of CTLs (Teff) with concomitant inc
Slide 10: Observed Complete Response in Subjects in Phase Melanoma Study
Observed Complete Response in 2 of 9 Subjects in Phase 1 Melanoma Study Subject 1 Subject 2 Ampligen (800mg twice weekly) Ampligen (300mg twice weekly) ——_—_——— oO Partial Response ¥ Partic Response a TUMOR MASS Complete Complete Response Response v VOLUME OF RIGHT AXILLARY TUMOR MASS z 2 fa) =< oO
Slide 11: Synergistic Effects in Combination with Checkpoint Inhibitor, Anti-PD-L1
synergistic Effects in Combination with Checkpoint Inhibitor, Anti-PD-L1 Pancreatic Cancer Mouse Model Synergistic Increase in Median Survival Synergistic Increase in Time to Progression — Control — Control i ee = 150) Ampligen _ 15 = Anti-PD-L1 E = contro! 3 = controt is 5 Z 15 ‘==:Ampligan: =z 15
Slide 12: Increase in Median Survival Combining Ampligen with Anti-PD-1
Increase in Median Survival Combining Ampligen with Anti-PD-1 Colorectal Carcinoma Mouse Model =—& Ampligentanti-PD-1 —@ anti-PD-1 =—@ control os = > Fe 5 ao oa © o oO bd o a UPMC LIFE CHANGING MEDICINE 12
Slide 13: Ongoing Clinical Studies Sponsored by UPMC
Ongoing Clinical Studies Sponsored by UPMC LIFE CHANGING MEDICINE Phase 1/2 Phase 2 Advanced, Recurrent Ovarian Cancer Advanced, Recurrent Ovarian Cancer Phase 1 portion fully enrolled Enrollment ongoing Intraperitoneal chemo-immunotherapy Cisplatin, pembrolizumab, plus Ampligen Data published Q1 20
Slide 14: Ongoing Clinical Studies Sponsored by Roswell Park
Phase 2a Stage 4 Colorectal Cancer Metastatic, Liver Enrollment ongoing Chemokine modulatory regimen Data expected: Q2 2022 PI: Dr. P. Boland Phase 2 Early-Stage Prostate Cancer Enrollment ongoing Aspirin and Ampligen with or without interferon-alpha 2b (Intron A) Data expected: not yet predictable
Slide 15: Promising Results Observed in Early Access Program (EAP)
Promising Results Observed in Early Access Program (EAP) Statistically Significant Increased Overall Survival Compared to Historical Controls in Treatment of Late-Stage Pancreatic Cancer Site: Erasmus University, The Netherlands, Eligibility: Adults with metastatic or locally conducted by Professor
Slide 16: Ampligen: SARS-CoV-2 (COVID-19)
aim Ampligen SARS-CoV-2 (COVID-19) 16
Slide 17: Ampligen May Mount a Potentially Broad-Spectrum Immune System Response Against SARS-CoV-2
Ampligen May Mount a Potentially Broad-Spectrum Immune System Response Against SARS-CoV-2 (COVID-19) Targeting toll-like receptor 3 (TLR3) pathways, which are among the primary pathways for antiviral protection (uniquely targets TLR3 without activation of the inflammatory cytosolic helicases) Potent
Slide 18: Ongoing Phase 1/2 Study for Treatment of COVID-19 Cancer Patients
Ongoing Phase 1/2 Study for Treatment of COVID-19 Cancer Patients Study Ongoing and Actively Recruiting Subjects Evaluating safety and effectiveness to reduce replication of SARS-CoV-2 virus from upper airway in patients and enhance and expand natural immunity (Intravenous) 18
Slide 19: Ampligen: Immune System Disorders (ISD)
Ampligen Immune System Disorders (ISD) SalM °
Slide 20: Ampligen for the Treatment of ME/CFS
Ampligen for the Treatment of ME/CFS Developing protocol for confirmatory Phase 3 trial, required for U.S. NDA Approved for the treatment of severe CFS in Argentina Toll-Like Receptor 3 agonist which is known to activate the innate immune system and induce immuno-modulation SAIM IimmunoTech
Slide 21: Chronic Illness Following COVID-19
Chronic Illness Following COVID-19 Chronic illness following recovery is prevalent Fatigue | Brain Fog | Dyspnea | Joint Pain | Chest Pain COVID-Induced Chronic Fatigue shares similarities to ME/CFS COVID-Induced Chronic Fatigue (Long COVID or ‘Long Haulers’) Post-COVID-19 Cognitive Impairment Amend
Slide 22: Corporate Overview
Corporate Overview
Slide 23: Intellectual Property Portfolio — Market Exclusivity
Intellectual Property Portfolio — Market Exclusivity 44 39 Patents Worldwide Pending Applications Orphan Drug Designation (FDA and EMA): Ampligen Indications: 7 years market exclusivity following FDA U.S. — Pancreatic Cancer, Melanoma, approval ME/CFS, Renal Cell Carcinoma, AIDS 10 years market excl
Slide 24: Financial Snapshot
Financial Snapshot NYSE American: AIM Sufficient Capital to Fund Operations Through Multiple Key Clinical Milestones A7.8M Shares Outstanding? N AIM 1: As of September 30, 2021; 2: As of January 14, 2022 with a closing price of $0.89; 3: NYSE American immunoTech
Slide 25: Upcoming Milestones Expected to Drive Value
Upcoming Milestones Expected to Drive Value Pancreatic Cancer Expressing TLR3 Receptors: Publication of Preclinical Data ¥ January 2022: Advanced Recurrent Ovarian Metastatic Triple-Negative Breast Cancer: Advanced Recurrent Ovarian 2 Cancer: Phase 1 Publication of Results Phase 1/2 Results Cancer:
Slide 26: Investment Summary
Investment Summary Immuno-Pharma Company with Broad Pipeline Across Multiple High-Value Indications in Oncology, Virology and Immune-Deficiency Lead program Ampligen has Leveraging external Growing body of data favorable safety profile and collaborators to fund potentially supports promising efficac
Slide 27: AIMIMMUNO.COM
AIMIMMUNO.COM NYSE AMERICAN:AIM ann ImmunoTech
AIM ImmunoTech — Investor Presentation (January 2022) on 6ix